Identification | Back Directory | [Name]
1H-1,2,3-Triazolo[4,5-b]pyrazine, 1-[[(2S)-4-[5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]-2-morpholinyl]methyl]-6-(1-methyl-1H-pyrazol-4-yl)- | [CAS]
1571903-56-4 | [Synonyms]
1H-1,2,3-Triazolo[4,5-b]pyrazine, 1-[[(2S)-4-[5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]-2-morpholinyl]methyl]-6-(1-methyl-1H-pyrazol-4-yl)- | [Molecular Formula]
C29H34N12O | [MOL File]
1571903-56-4.mol | [Molecular Weight]
566.66 |
Hazard Information | Back Directory | [Description]
Vabametkib is a hepatocyte growth factor receptor (HGFR) inhibitor for use as an antineoplastic agent. | [Uses]
Vabametkib is a potent inhibitor of hepatocyte growth factor receptor (HGFR). Vabametkib inhibits Hs746T cells proliferation and inhibits c-Met with an IC50 value of 7 nM. Vabametkib can be used as an antineoplastic agent[1][2]. | [References]
[1] WHO Drug Informat ion - World Health Organization (WHO). [2] Jung Hui Jeong, et al. Preparation of triazolopyrazine derivatives as c-Met kinase inhibitors: Korea, Republic of, KR2014022229. 2014-02-24. [3] WHO Drug Information-World Health Organization (WHO). |
|
|